Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
49.13
-0.73 (-1.46%)
Nov 21, 2024, 11:29 AM EST - Market open
Cytokinetics Employees
Cytokinetics had 423 employees as of December 31, 2023. The number of employees increased by 14 or 3.42% compared to the previous year.
Employees
423
Change (1Y)
14
Growth (1Y)
3.42%
Revenue / Employee
$7,610
Profits / Employee
-$1,362,652
Market Cap
5.80B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 423 | 14 | 3.42% |
Dec 31, 2022 | 409 | 156 | 61.66% |
Dec 31, 2021 | 253 | 69 | 37.50% |
Dec 31, 2020 | 184 | 28 | 17.95% |
Dec 31, 2019 | 156 | 26 | 20.00% |
Dec 31, 2018 | 130 | -7 | -5.11% |
Dec 31, 2017 | 137 | 10 | 7.87% |
Dec 31, 2016 | 127 | 27 | 27.00% |
Dec 31, 2015 | 100 | 8 | 8.70% |
Dec 31, 2014 | 92 | 7 | 8.24% |
Dec 31, 2013 | 85 | 15 | 21.43% |
Dec 31, 2012 | 70 | -9 | -11.39% |
Dec 31, 2011 | 79 | -26 | -24.76% |
Dec 31, 2010 | 105 | -6 | -5.41% |
Dec 31, 2009 | 111 | 1 | 0.91% |
Dec 31, 2008 | 110 | -51 | -31.68% |
Dec 31, 2007 | 161 | 13 | 8.78% |
Dec 31, 2006 | 148 | -2 | -1.33% |
Dec 31, 2005 | 150 | -20 | -11.76% |
Dec 31, 2004 | 170 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Grifols | 23,737 |
Elanco Animal Health | 9,800 |
RadNet | 8,441 |
Merit Medical Systems | 6,950 |
Blueprint Medicines | 655 |
Halozyme Therapeutics | 373 |
Corcept Therapeutics | 352 |
CYTK News
- 2 days ago - Bayer acquires rights to Cytokinetics' heart drug in Japan - Reuters
- 2 days ago - Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan - GlobeNewsWire
- 5 days ago - Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - GlobeNewsWire
- 5 days ago - Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - GlobeNewsWire
- 10 days ago - Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089 - GlobeNewsWire
- 14 days ago - Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Cytokinetics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 16 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire